title: No relationship between 18F-fluorodeoxyglucose positron emission tomography and expression of Glut-1 and -3 and hexokinase I and II in high-grade glioma.
abstract: The purpose of this study was to compare glucose metabolism, measured using 18F-fluorodeoxyglucose positron emission tomography ([18F]FDG-PET), with the expression of Glut-1 and -3 and hexokinase I (Hex I) and II in high-grade glioma. The retrospective study involved 27 patients with WHO classification grade III and IV glioma, with either newly diagnosed or recurrent tumours. Patients underwent dynamic and static [18F]FDG-PET to glucose metabolic rate (MRGlu) and standardised uptake value (SUV), respectively. Tumour biopsies were obtained and stained using immunohistochemistry for the expression of Glut-1, -3, Hex I and II. Relationships between variables were studied using Spearman's rank correlation test. Results showed that the expression of Glut-1, Glut-3, Hex I and Hex II varied between and within the tumour samples. The mean of MRGlu was 0.2 (range 0.09-0.25) micromol/min/ml and that of SUV was 4.2 (range 3.2-5.2). There were no significant relationships among the tumour expression of any of the proteins studied with either MRGlu or SUV (p>0.21 for all). In conclusion, the lack of relationship between the immunohistochemical expression of Glut-1, -3, Hex I or II and glucose metabolism measured using [18F]FDG-PET in patients with high-grade glioma may be due to the tissue heterogeneity and presence of necrosis in high-grade tumours.
authors.affiliation: Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK. natalie.charnley@manchester.ac.uk
authors.forename: N
authors.initials: N
authors.lastname: Charnley
authors.forename: R
authors.initials: R
authors.lastname: Airley
authors.forename: D
authors.initials: D
authors.lastname: Du Plessis
authors.forename: C
authors.initials: C
authors.lastname: West
authors.forename: C
authors.initials: C
authors.lastname: Brock
authors.forename: C
authors.initials: C
authors.lastname: Barnett
authors.forename: J
authors.initials: J
authors.lastname: Matthews
authors.forename: K
authors.initials: K
authors.lastname: Symonds
authors.forename: M
authors.initials: M
authors.lastname: Bottomly
authors.forename: R
authors.initials: R
authors.lastname: Swindell
authors.forename: P
authors.initials: P
authors.lastname: Price
mesh_terms: D001254:Astrocytoma / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D014408:Biomarkers, Tumor / Q000378:metabolism; D001932:Brain Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D019788:Fluorodeoxyglucose F18; D005947:Glucose / Q000378:metabolism; D051272:Glucose Transporter Type 1 / Q000378:metabolism*; D051274:Glucose Transporter Type 3 / Q000378:metabolism*; D006593:Hexokinase / Q000378:metabolism*; D006801:Humans; D007124:Immunoenzyme Techniques; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D019275:Radiopharmaceuticals; D012189:Retrospective Studies
chemical_list: D014408:Biomarkers, Tumor; D051272:Glucose Transporter Type 1; D051274:Glucose Transporter Type 3; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; C472074:HK1 protein, human; D006593:Hexokinase; D005947:Glucose